Research Article

Safety Characterization and Antimicrobial Properties of Kefir-Isolated *Lactobacillus kefir*

Paula Carasi,¹ Mariángeles Díaz,¹ Silvia M. Racedo,² Graciela De Antoni,¹ María C. Urdaci,² and María de los Angeles Serradell¹

¹ Cátedra de Microbiología, Departamento de Ciencias Biológicas, de La Plata, 47 y 115 s/n, CP, 1900 La Plata, Argentina

² Laboratoire de Microbiologie et Biochimie Appliquée (LBMA), Université de Bordeaux, UMR 5248, Bordeaux Sciences Agro, 1 Cours du Général de Gaulle, 33175 Gradignan, France

Correspondence should be addressed to María de los Angeles Serradell; maserr@biol.unlp.edu.ar

Received 20 February 2014; Revised 17 April 2014; Accepted 21 April 2014; Published 13 May 2014

Academic Editor: María Fernández

Copyright © 2014 Paula Carasi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Lactobacilli are generally regarded as safe; however, certain strains have been associated with cases of infection. Our workgroup has already assessed many functional properties of *Lactobacillus kefir*, but parameters regarding safety must be studied before calling them probiotics. In this work, safety aspects and antimicrobial activity of *L. kefir* strains were studied. None of the *L. kefir* strains tested caused α - or β -hemolysis. All the strains were susceptible to tetracycline, clindamycin, streptomycin, ampicillin, erythromycin, kanamycin, and gentamicin; meanwhile, two strains were resistant to chloramphenicol. On the other hand, all *L. kefir* strains were able to inhibit both Gram(+) and Gram(−) pathogens. Regarding the *in vitro* results, *L. kefir* CIDCA 8348 was selected to perform *in vivo* studies. Mice treated daily with an oral dose of 10^8 CFU during 21 days showed no signs of pain, lethargy, dehydration, or diarrhea, and the histological studies were consistent with those findings. Moreover, no differences in proinflammatory cytokines secretion were observed between treated and control mice. No translocation of microorganisms to blood, spleen, or liver was observed. Regarding these findings, *L. kefir* CIDCA 8348 is a microorganism isolated from a dairy product with a great potential as probiotic for human or animal use.

1. Introduction

Kefir grains are composed of a complex community of yeasts, lactic acid, and acetic acid bacteria confined in a matrix of polysaccharides and proteins [1]. The product obtained by fermentation of milk using these grains is called “kefir” and several health-promoting properties have been associated to its consumption [2–5].

As it is known, probiotics are “live microorganisms which, administered in adequate amounts, exert a beneficial effect to the health of the host” [6]. Specific strains of lactic acid bacteria, in particular some of the genera *Lactobacillus*, are extensively used as probiotics [7, 8] since their ability to modulate the immune system has been demonstrated [9, 10] as well as their capacity to inhibit the growth or invasion of pathogenic bacteria and parasites [11–13].

The study of the beneficial properties attributed to isolated microorganisms constitutes a field of great interest

for the development of functional foods. Lactobacilli are generally regarded as safe (GRAS) and most of them (as *Lactobacillus kefir*) are included in the QPS list of the European Union [14] due to their long history of use in fermented dairy products and their presence in human intestinal tract. However, certain *Lactobacillus* strains have been associated with cases of sepsis, endocarditis, or bacteremia, mostly in association with a severe underlying disease [15–18]. On the other hand, the absence of the acquired antimicrobial resistance is a very important criterion for evaluating the safety of lactic acid bacteria (LAB) used as food started or probiotics [19]. The breakpoints for the antibiotic list were defined by the European Food Safety Authority (EFSA) in order to assess the bacterial resistance to antibiotics of human or veterinary importance [20, 21].

Our workgroup has isolated and characterized numerous species of LAB and yeasts from kefir, including several strains of *Lactobacillus kefir* [22–24], one of the most predominant

TABLE 1: Minimum inhibitory concentrations (MIC) for antibiotic resistance.

Antibiotics	Breakpoints ^a	MIC (mg L ⁻¹)					
		CIDCA 8321	CIDCA 8345	CIDCA 8348	CIDCA 83115	CIDCA 83111	CIDCA 83113
Ampicillin	2	<0.032	<0.032	<0.032	<0.032	<0.032	<0.032
Clindamycin	1	<0.032	<0.032	<0.032	<0.032	<0.032	<0.032
Chloramphenicol	4	8	16	2	2	1	2
Erythromycin	1	<0.125	<0.125	<0.125	<0.125	<0.125	<0.125
Gentamicin	16	<0.5	<0.5	<0.5	<0.5	<0.5	<0.5
Kanamycin	32	<2	<2	<2	<2	<2	<2
Streptomycin	64	<0.5	<0.5	<0.5	<0.5	<0.5	<0.5
Tetracycline	8	<0.125	<0.125	4	2	4	<0.125

^aThese are the recommended breakpoints for heterofermentative lactobacilli EFSA Panel on Additives and Products or Substances used in Animal Feed (2012) [20].

species present in kefir-fermented milk (ranged from 2×10^8 to 1×10^9 *L. kefir* cells mL⁻¹) [25].

We have already demonstrated the potential of *L. kefir* as a probiotic microorganism *in vitro* after verifying that secretion products and surface proteins from these heterofermentative lactobacilli exert a protective action against the invasion of *Salmonella enterica* serovar Enteritidis [26] and that they are able to antagonize the cytotoxic effects of clostridial toxins on Vero cells [27]. On the other hand, it has been demonstrated that *L. kefir* strains are able to preserve a high percentage of viability after both spray-drying [28, 29] and freeze-drying procedures [30]. However, no parameter regarding *L. kefir*'s safety was ever evaluated. Since it is known that both the beneficial properties such as harmful characteristic are dependent on the strain, the individual study of the safety of potential probiotic microorganisms should be considered.

Taking into account the potential of *L. kefir* as a novel probiotic, we reported in this work some safety characteristics of *L. kefir* strains, as well as the capacity of strains to produce antimicrobial compounds against some intestinal pathogens.

2. Materials and Methods

2.1. Bacterial Strains and Culture Conditions. Pure cultures used in this study comprised *Lactobacillus kefir* strains CIDCA 8321, 8345, 8348, 83111, 83113, and 83115 [23, 31]. These bacteria were cultured in MRS (Difco, Detroit, USA) for 48 h at 37°C. The following pathogenic bacteria were also used, *Enterococcus faecalis* ATCC 29212, *Staphylococcus aureus* ATCC 6538, *Shigella flexneri* ATCC 9199, *Pseudomonas aeruginosa* ATCC 15442, a clinical isolate of *Salmonella enterica* serovar Enteritidis CIDCA 101 (Hospital de Pediatría Professor Juan P. Garrahan, Buenos Aires, Argentina), enterohemorrhagic *Escherichia coli* EDL 933, *Listeria monocytogenes* ATCC 7644, and *Bacillus cereus* ATCC 10876. All mentioned strains, except *B. cereus*, were grown using brain heart infusion (BHI) broth (Biokar Diagnostics, Beauvais, France) in agitation at 37°C for 16 h. *B. cereus* was grown in BHI growth supplemented with dextrose (Anedra, Argentina) 1 g L⁻¹ (BHIg) in agitation at 37°C for 16 h.

2.2. Hemolysis. Hemolysis was tested by growth of the strains on LAPTg agar (peptone 15 g L⁻¹; tryptone 10 g L⁻¹; dextrose 10 g L⁻¹; yeast extract 10 g L⁻¹; Tween 80 1 g L⁻¹; and bacteriological agar 15 g L⁻¹) supplemented with 5% human blood (group O) and incubated for 48 h at 37°C under aerobic conditions. The appearance of clear zones around the bacterial colonies indicated the presence of β -hemolysis whereas green zones around the colonies suggested α -hemolysis. *Enterococcus faecalis* ATCC 29212 was included as a positive hemolytic control.

2.3. Minimum Inhibitory Concentration (MIC) for Antibiotic Resistance. The minimum inhibitory concentrations (MICs) of the antimicrobial agents tested (Table 1) were determined by broth microdilution according to the ISO 10932/IDF 233 standard from 2010 [32]. All antibiotics (Sigma-Aldrich, USA) were dissolved for preparing stock solutions of 1280 μ g mL⁻¹. Stock solutions were diluted in LSM broth (90% IST plus 10% MRS) to obtain solutions with preliminary concentrations in the range of 0.25–128 μ g mL⁻¹. Bacterial inocula were prepared by suspending colonies from 48 h incubated in MRS medium to 5 mL 0.85% NaCl solution. Subsequently, inocula were adjusted to OD_{625 nm} 0.18–0.24 and diluted 1:500 in LSM broth for inoculation of microdilution plates by adding 50 μ L of diluted inoculum to each well containing 50 μ L of an antibiotic solution. In these conditions, the bacterial inoculum was around $2\text{--}3 \times 10^5$ CFU mL⁻¹ in the wells. After incubating plates under anaerobic conditions at 37°C for 48 hours, the MICs value was read as the lowest concentration of an antimicrobial agent in which visible growth was inhibited.

MICs results were compared with the recommended breakpoints for heterofermentative lactobacilli by the EFSA Panel on Additives and Products or Substances used in Animal Feed [20].

2.4. PCR Detection of Chloramphenicol Resistance Gene. *Cat*, chloramphenicol acetyltransferase gene, was assessed using the primers and PCR conditions described by Hummel et al. [33]. A plasmid from *L. reuteri* G4 was used as a positive control.

2.5. Growth Inhibition of Bacterial Pathogens. The agar spot test described by Schillinger and Lücke [34] was used. Briefly, 5 μ L of a suspension OD_{625 nm} 1 of *L. kefir* strains was spotted into MRS agar and incubated for 24 h at 37°C. The following day, pathogens were seeded into soft BHI agar and plated over the spotted lactobacilli. After 18 h of incubation at 37°C, the inhibition halos were measured. The width of the clear zone (*R*) was calculated as follows: $R = (d_{\text{Inhib}} - d_{\text{Spot}})/2$, where d_{Inhib} is the diameter of the zone without pathogen growth and d_{Spot} is the diameter of the spot. Inhibition scores are as follows: negative (–), $R < 2$ mm; low inhibition capacity (+), $2 \text{ mm} < R < 5$ mm; and high inhibition capacity (++), $R > 6$ mm. At least three independent experiments were performed.

2.6. In Vivo Studies

2.6.1. Ethics Statement. All animal procedures were performed in strict accordance with the guidelines issued by the European Economic Community “86/609.”

2.6.2. Experimental In Vivo Protocol. Male 6-week-old Swiss albino mice (Janvier, Le Genest Isle, France) were quarantined 2 weeks after arrival and then randomized by body weight into experimental and control groups of 5–7 animals each. Mice were housed under standard laboratory conditions with free access to food and water. The temperature was kept at 22°C and a 12-hour light/dark schedule was maintained. Mice received by gavage 10^8 CFU of *L. kefir* CIDCA 8348 (Lk group) or PBS (control group) daily for 21 days.

2.6.3. Safety Evaluation. Mice were weighted every two days; behavior and signs of pain were analyzed daily [35]. At the end of the experimental protocol, ileum and colon were removed and histological studies were performed using hematoxylin-eosin staining [36].

2.6.4. Translocation Assay. Liver and spleen were removed and blood samples were collected aseptically. Liver and spleen were homogenized in 0.1% sterile PBS (0.1 g of organ per mL) and serially diluted. One hundred microliters of each organ homogenate or blood was plated on VRBG Agar (Biokar Diagnostics, Beauvais, France) for enterobacteria and MRS agar for LAB. Plates were incubated under aerobic conditions for 24 h at 37°C for VRBG and for 48 h at 37°C for MRS before examination.

2.6.5. Microorganism Counts in the Ileum. Ileum content was washed with 1 mL sterile PBS and then serial dilutions were plated as indicated above.

2.6.6. Cytokine Release by Intestine and Colon Explants. Explants were cultured in RPMI medium supplemented with 10% foetal bovine serum (Gibco-Invitrogen, Carlsbad, CA, USA), 10 mg/L streptomycin and 10 IU/mL penicillin G, and 100 mg/L gentamicin (all from Sigma Chemical Co., St. Louis,

FIGURE 1: Body weight gain of treated (Lk) and control mice along 21 days of *L. kefir* CIDCA 8348 administration. No differences were observed between control mice and Lk mice ($P > 0.05$).

MO, USA) for 24 h at 37°C in a 5% (v/v) CO₂-95% (v/v) air atmosphere [37, 38]. Supernatants were collected, centrifuged, and frozen for cytokines (IL-6, IL-17A, TNF- α , IFN- γ , and GM-CSF) measurements (eBioscience Ready Set Go, France). All assays were performed according to the manufacturer's instructions.

3. Results and Discussion

In the present work, six potentially probiotic *L. kefir* strains isolated from kefir were studied in order to evaluate both their safety and antimicrobial properties.

Since hemolysis is a common virulence factor among pathogens, the first safety parameter evaluated *in vitro* was bacterial hemolytic activity. In this study, none of the *L. kefir* strains tested caused α - or β -hemolysis (data not shown). In this genus, hemolytic activity has a very low frequency and only α -hemolysis has been reported for lactobacilli isolated from foods and dairy products [39–41].

Another important feature regarding safety is the sensitivity to antibiotics. The results obtained for *L. kefir* strains are shown in Table 1. All tested bacteria exhibited MIC values lower than the breakpoints recommended for heterofermentative lactobacilli [20] for tetracycline, clindamycin, streptomycin, ampicillin, erythromycin, kanamycin, and gentamicin. However, the strains CIDCA 8321 and 8345 were resistant to chloramphenicol although the amplification of CAT encoding gene was negative for all the *L. kefir* strains (data not shown). In this regard, Hummel et al. [33] reported that some lactobacilli strains carrying *cat* genes were susceptible to chloramphenicol; meanwhile, in other resistant strains *cat* genes could not be amplified. Further research, such as the study of the distribution of chloramphenicol MICs, could contribute to determine whether resistance is acquired (not acceptable strain) or intrinsic (acceptable strain) according to EFSA [21].

To our knowledge, antibiotic sensitivity of *L. kefir* was evaluated just in two publications. Nawaz et al. [42] studied

TABLE 2: Antimicrobial activity of *Lactobacillus kefir* strains against pathogens by agar spot test.

Strain	Growth inhibition ability					
	CIDCA 8321	CIDCA 8345	CIDCA 8348	CIDCA 83115	CIDCA 83111	CIDCA 83113
Gram negative bacilli						
<i>Pseudomona aeruginosa</i>	++	+	++	+	+	+
<i>Salmonella</i> Enteritidis	+	–	+	–	+	+
<i>Shigella flexneri</i>	+	–	+	–	+	–
EHEC	–	–	–	–	–	–
Gram positive bacilli						
<i>Listeria monocytogenes</i>	+	–	+	–	+	–
<i>Bacillus cereus</i>	++	+	++	+	+	++
Gram positive cocci						
<i>Enterococcus faecalis</i>	+	–	+	–	–	–
<i>Staphylococcus aureus</i>	++	+	++	+	++	+

FIGURE 2: Hematoxylin-eosin staining of ileum and colon section. (a) Ileum of control mice; (b) ileum of mice receiving *L. kefir* CIDCA 8348 for 21 days; (c) colon of control mice; (d) colon of mice receiving *L. kefir* CIDCA 8348 for 21 days. No differences were observed among groups in any tissue.

one *L. kefir* strain isolated from a dairy product, which was resistant to kanamycin and tetracycline but sensitive to other antimicrobial agents tested in LSM medium. Chang et al. [43] observed that all the *L. kefir* strains, among other lactobacilli, isolated from swine intestines were resistant to tetracycline, with MIC values higher than $256 \mu\text{g mL}^{-1}$, and that they possessed at least one resistance gene. Taking into account that tetracycline is the most widely used antimicrobial agent in swine production, its continuous administration might be selecting tetracycline resistant microorganisms on swine's microbiota. This feature and the different origin of our *L. kefir* strains could contribute, at least in part, to the disagreement between our results and those from other authors.

The secretion of molecules able to inhibit the growth of pathogens is a desirable characteristic, among others, for a potentially probiotic bacteria [44], and it could also be a technological advantage in the food industry since they might be used as functional starter cultures [45, 46]. We evaluated the pathogen growth inhibition capacity of the six *L. kefir* strains studied. As observed in Table 2, the inhibition profile

was strain dependent, and Gram positive pathogens showed higher sensibility to *L. kefir* strains than Gram negative bacteria. It is important to notice that the addition of MRS acidified with HCl or lactic acid to pH 4.3 (final pH reached by *L. kefir* cultures) was not able to produce inhibition of pathogens in our tests (data not shown). All the strains inhibited growth of *Bacillus cereus* and *Staphylococcus aureus* but none of them inhibited enterohemorrhagic *Escherichia coli* (EHEC). The strains *L. kefir* CIDCA 8321, CIDCA 8348, and CIDCA 83111 were able to inhibit growth of the rest of the tested pathogens. Many mechanisms associated with bacterial inhibition have been described for *Lactobacillus* species [47]. The production of antimicrobial molecules is usually strain dependent, which is in accordance with our results, and the introduction of probiotic bacteria able to inhibit other microorganisms could have a positive impact in animal and human health [48, 49].

Up to here, *L. kefir* CIDCA 8321, 8348, and 83111 demonstrated to be the most active strains against pathogens; however, CIDCA 8321 showed resistance to chloramphenicol. In consequence, among the other two strains, we selected CIDCA 8348 to perform *in vivo* studies in Swiss mice.

FIGURE 3: Secretion of proinflammatory cytokines by intestine and colon explants from mice receiving *L. kefir* CIDCA 8348 for 21 days (Lk) and control mice determined by ELISA. Statistical analysis: one way ANOVA, posttest Bonferroni, $\alpha = 0.05$.

As observed in Figure 1, no differences in body weight were observed between mice that received $100 \mu\text{L}$ of a 10^9 CFU mL^{-1} suspension of *L. kefir* CIDCA 8348 (Lk group) and mice receiving $100 \mu\text{L}$ of PBS (control group) daily for 21 days. Moreover, there were no differences in food and water intake between groups (data not shown). In accordance with these results, Lk group did not show any signs of pain, lethargy, dehydration, or diarrhea during treatment. No signs of inflammation or damage were observed in any organ during necropsy. Length of each mouse's colon was measured, since it has been reported that increasing levels of inflammation result in shortening of the colon [50]. No significant differences in colon's length of Lk mice and control mice were observed (12.4 ± 0.6 versus 12.6 ± 0.8). Moreover, the histological study of ileum and colon was consistent with the already described observations; no signs of inflammation, edema, erosion/ulceration, crypt loss, or infiltration of mono- and polymorphonuclear cells [51] were observed in Lk mice's tissues (Figure 2), in concordance with previous report by Bolla et al. [30] who administered this strain as a constituent of a mixture of five kefir-isolated microorganisms to BALB/c mice. Additionally, no differences in the secretion levels for proinflammatory cytokines such as IL-6, IL-17A, IFN- γ ,

TNF- α , and GM-CSF were observed in the small intestine and colon explants from Lk and control mice (Figure 3). On the other hand, no translocation of microorganisms was observed on blood, spleen, or liver (bacterial counts were negative), which means that the epithelial barrier was not disrupted since intestinal permeability was not affected by *L. kefir* CIDCA 8348 administration [52]. Besides, the viable counts of enterobacteria ($3.5 \pm 0.8 \times 10^7$ versus $4.8 \pm 0.9 \times 10^7$) and LAB ($1.1 \pm 0.6 \times 10^7$ versus $2.6 \pm 0.8 \times 10^7$) in the ileum were comparable between control and treated mice.

4. Conclusion

Taking into account all these findings, we conclude that *L. kefir* CIDCA 8348 isolated from a dairy product present a great potential as probiotic for human or animal use and can be used also for producing functional foods.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported by Agencia Nacional de Promoción Científica y Tecnológica, CONICET, Universidad Nacional de La Plata (Project 11/X548), and Bordeaux Science Agro, Ministère de l'Agriculture Français. P. Carasi is a fellow of CONICET; M. Díaz is a fellow of the Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CIC-PBA); G. De Antoni is a researcher of CIC-PBA; M. Serradell is a member of the Carrera de Investigador Científico y Tecnológico of CONICET. Silvia M. Racedo and María C. Urdaci are researchers of Bordeaux Science Agro, Université de Bordeaux. P. Carasi was supported by Boehringer Ingelheim Fonds (travel grants programme).

References

- [1] G. Garrote, A. Abraham, and G. de Antoni, "Microbial interactions in kefir: a natural probiotic drink," in *Biotechnology of Lactic Acid Bacteria: Novel Applications*, F. Mozzi, R. R. Raya, and G. M. Vignolo, Eds., no. 1980, Wiley-Blackwell, Oxford, UK, 2010.
- [2] M. Correa Franco, M. A. Golowczyc, G. L. de Antoni, P. F. Pérez, M. Humen, and M. D. L. A. Serradell, "Administration of kefir-fermented milk protects mice against *Giardia intestinalis* infection," *Journal of Medical Microbiology*, vol. 62, part 12, pp. 1815–1822, 2013.
- [3] Z. B. Guzel-Seydim, T. Kok-Tas, A. K. Greene, and A. C. Seydim, "Review: functional properties of kefir," *Critical Reviews in Food Science and Nutrition*, vol. 51, no. 3, pp. 261–268, 2011.
- [4] E. J. Kakisu, A. G. Abraham, P. F. Pérez, and G. L. de Antoni, "Inhibition of *Bacillus cereus* in milk fermented with kefir grains," *Journal of Food Protection*, vol. 70, no. 11, pp. 2613–2616, 2007.
- [5] C. G. Vinderola, J. Duarte, D. Thangavel, G. Perdigón, E. Farnworth, and C. Matar, "Immunomodulating capacity of kefir," *Journal of Dairy Research*, vol. 72, no. 2, pp. 195–202, 2005.
- [6] FAO/WHO, *Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria*, 2001, http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf.
- [7] M. Bernardeau, J. P. Vernoux, S. Henri-Dubernet, and M. Guéguen, "Safety assessment of dairy microorganisms: the *Lactobacillus* genus," *International Journal of Food Microbiology*, vol. 126, no. 3, pp. 278–285, 2008.
- [8] M. Dušková, O. Šedo, K. Kšicová, Z. Zdráhal, and R. Karpíšková, "Identification of lactobacilli isolated from food by genotypic methods and MALDI-TOF MS," *International Journal of Food Microbiology*, vol. 159, no. 2, pp. 107–114, 2012.
- [9] B. Corthésy, H. R. Gaskins, and A. Mercenier, "Cross-talk between probiotic bacteria and the host immune system," *Journal of Nutrition*, vol. 137, no. 3, pp. 781–790, 2007.
- [10] J. M. Wells, "Immunomodulatory mechanisms of lactobacilli," *Microbial Cell Factories*, vol. 10, supplement 1, p. S17, 2011.
- [11] A. A. Hugo, E. Kakisu, G. L. de Antoni, and P. F. Pérez, "Lactobacilli antagonize biological effects of enterohaemorrhagic *Escherichia coli* in vitro," *Letters in Applied Microbiology*, vol. 46, no. 6, pp. 613–619, 2008.
- [12] M. A. Humen, G. L. de Antoni, J. Benyacoub et al., "*Lactobacillus johnsonii* La1 antagonizes *Giardia intestinalis* in vivo," *Infection and Immunity*, vol. 73, no. 2, pp. 1265–1269, 2005.
- [13] A. L. Servin, "Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens," *FEMS Microbiology Reviews*, vol. 28, no. 4, pp. 405–440, 2004.
- [14] EFSA Panel on Biological Hazards (BIOHAZ), "Scientific opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2012 update)," *EFSA Journal*, vol. 10, no. 12, p. 3020, 2012.
- [15] P. A. Fradiani, A. Petrucca, F. Ascenzioni et al., "Endocarditis caused by *Lactobacillus jensenii* in an immunocompetent patient," *Journal of Medical Microbiology*, vol. 59, no. 5, pp. 607–609, 2010.
- [16] F. Gouriet, M. Million, M. Henri, P.-E. Fournier, and D. Raoult, "*Lactobacillus rhamnosus* bacteremia: an emerging clinical entity," *European Journal of Clinical Microbiology and Infectious Diseases*, vol. 31, no. 9, pp. 2469–2480, 2012.
- [17] M. H. Land, K. Rouster-Stevens, C. R. Woods, M. L. Cannon, J. Cnota, and A. K. Shetty, "*Lactobacillus* sepsis associated with probiotic therapy," *Pediatrics*, vol. 115, no. 1, pp. 178–181, 2005.
- [18] I. Suárez-García, A. Sánchez-García, L. Soler, E. Malmierca, and J. Gómez-Cerezo, "*Lactobacillus jensenii* bacteremia and endocarditis after dilatation and curettage: case report and literature review," *Infection*, vol. 40, no. 2, pp. 219–222, 2012.
- [19] S. Mayrhofer, K. J. Domig, C. Mair, U. Zitz, G. Huys, and W. Kneifel, "Comparison of broth microdilution, Etest, and agar disk diffusion methods for antimicrobial susceptibility testing of *Lactobacillus acidophilus* group members," *Applied and Environmental Microbiology*, vol. 74, no. 12, pp. 3745–3748, 2008.
- [20] EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), "Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance," *EFSA Journal*, vol. 10, no. 6, pp. 1–10, 2012.
- [21] EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), "Technical guidance—update of the criteria used in the assessment of bacterial resistance to antibiotics of human or veterinary importance," *EFSA Journal*, vol. 732, pp. 1–15, 2008.
- [22] A. Bosch, M. A. Golowczyc, A. G. Abraham, G. L. Garrote, G. L. de Antoni, and O. Yantorno, "Rapid discrimination of lactobacilli isolated from kefir grains by FT-IR spectroscopy," *International Journal of Food Microbiology*, vol. 111, no. 3, pp. 280–287, 2006.
- [23] G. L. Garrote, A. G. Abraham, and G. L. de Antoni, "Chemical and microbiological characterisation of kefir grains," *Journal of Dairy Research*, vol. 68, no. 4, pp. 639–652, 2001.
- [24] M. F. Hamet, A. Londero, M. Medrano et al., "Application of culture-dependent and culture-independent methods for the identification of *Lactobacillus kefirianofaciens* in microbial consortia present in kefir grains," *Food Microbiology*, vol. 36, no. 2, pp. 327–334, 2013.
- [25] G. L. Garrote, M. A. Serradell, A. G. Abraham, M. C. Añon, C. A. Fossati, and G. L. de Antoni, "Development of an immunochemical method to detect *Lactobacillus kefir*," *Food and Agricultural Immunology*, vol. 16, no. 3, pp. 221–233, 2005.
- [26] M. A. Golowczyc, P. Mobili, G. L. Garrote, A. G. Abraham, and G. L. de Antoni, "Protective action of *Lactobacillus kefir* carrying S-layer protein against *Salmonella enterica* serovar Enteritidis," *International Journal of Food Microbiology*, vol. 118, no. 3, pp. 264–273, 2007.
- [27] P. Carasi, F. M. Trejo, P. F. Pérez, G. L. de Antoni, and M. D. L. A. Serradell, "Surface proteins from *Lactobacillus kefir* antagonize

- in vitro* cytotoxic effect of *Clostridium difficile* toxins,” *Anaerobe*, vol. 18, no. 1, pp. 135–142, 2012.
- [28] M. A. Golowczyc, J. Silva, P. Teixeira, G. L. de Antoni, and A. G. Abraham, “Cellular injuries of spray-dried *Lactobacillus* spp. isolated from kefir and their impact on probiotic properties,” *International Journal of Food Microbiology*, vol. 144, no. 3, pp. 556–560, 2011.
- [29] M. A. Golowczyc, J. Silva, A. G. Abraham, G. L. de Antoni, and P. Teixeira, “Preservation of probiotic strains isolated from kefir by spray drying,” *Letters in Applied Microbiology*, vol. 50, no. 1, pp. 7–12, 2010.
- [30] P. A. Bolla, M. D. L. A. Serradell, P. J. de Urraza, and G. L. de Antoni, “Effect of freeze-drying on viability and *in vitro* probiotic properties of a mixture of lactic acid bacteria and yeasts isolated from kefir,” *Journal of Dairy Research*, vol. 78, no. 1, pp. 15–22, 2011.
- [31] P. Carasi, N. M. Ambrosio, G. L. de Antoni, P. Bressollier, M. C. Urdaci, and M. D. L. A. Serradell, “Adhesion properties of potentially probiotic *Lactobacillus kefir* to gastrointestinal mucus,” *Journal of Dairy Research*, vol. 81, no. 1, pp. 16–23, 2014.
- [32] ISO (International Organization for Standardization), “Milk and milk products—determination of the minimal inhibitory concentration (MIC) of antibiotics applicable to bifidobacteria and non-enterococcal lactic acid bacteria (LAB),” ISO 10932:2010 (IDF 223:2010), 2010.
- [33] A. S. Hummel, C. Hertel, W. H. Holzapfel, and C. M. A. P. Franz, “Antibiotic resistances of starter and probiotic strains of lactic acid bacteria,” *Applied and Environmental Microbiology*, vol. 73, no. 3, pp. 730–739, 2007.
- [34] U. Schillinger and F. K. Lücke, “Antibacterial activity of *Lactobacillus sake* isolated from meat,” *Applied and Environmental Microbiology*, vol. 55, no. 8, pp. 1901–1906, 1989.
- [35] D. J. Langford, A. L. Bailey, M. L. Chanda et al., “Coding of facial expressions of pain in the laboratory mouse,” *Nature Methods*, vol. 7, no. 6, pp. 447–449, 2010.
- [36] P. A. Bolla, P. Carasi, M. D. L. A. Bolla, G. L. de Antoni, and M. Serradell, “Protective effect of a mixture of kefir-isolated lactic acid bacteria and yeasts in a hamster model of *Clostridium difficile* infection,” *Anaerobe*, vol. 21, pp. 28–33, 2013.
- [37] L. Chatelais, A. Jamin, C. G. Guen, J. Lallès, I. le Huërou-Luron, and G. Boudry, “The level of protein in milk formula modifies ileal sensitivity to LPS later in life in a piglet model,” *PLoS ONE*, vol. 6, no. 5, Article ID e19594, 2011.
- [38] S. Dionne, S. Laberge, C. Deslandres, and E. G. Seidman, “Modulation of cytokine release from colonic explants by bacterial antigens in inflammatory bowel disease,” *Clinical and Experimental Immunology*, vol. 133, no. 1, pp. 108–114, 2003.
- [39] D. B. Adimpong, D. S. Nielsen, K. I. Sørensen, P. M. F. Derkx, and L. Jespersen, “Genotypic characterization and safety assessment of lactic acid bacteria from indigenous African fermented food products,” *BMC Microbiology*, vol. 12, no. 1, pp. 75–86, 2012.
- [40] P. M. Kaktcham, N. F. Zambou, F. M. Tchouanguep, M. El-Soda, and M. I. Choudhary, “Antimicrobial and safety properties of lactobacilli isolated from two Cameroonian traditional fermented foods,” *Scientia Pharmaceutica*, vol. 80, no. 1, pp. 189–203, 2012.
- [41] P. A. Maragkoudakis, G. Zoumpopoulou, C. Miaris, G. Kalantzopoulos, B. Pot, and E. Tsakalidou, “Probiotic potential of *Lactobacillus* strains isolated from dairy products,” *International Dairy Journal*, vol. 16, no. 3, pp. 189–199, 2006.
- [42] M. Nawaz, J. Wang, A. Zhou et al., “Characterization and transfer of antibiotic resistance in lactic acid bacteria from fermented food products,” *Current Microbiology*, vol. 62, no. 3, pp. 1081–1089, 2011.
- [43] Y.-C. Chang, C.-Y. Tsai, C.-F. Lin, Y.-C. Wang, I.-K. Wang, and T.-C. Chung, “Characterization of tetracycline resistance lactobacilli isolated from swine intestines at western area of Taiwan,” *Anaerobe*, vol. 17, no. 5, pp. 239–245, 2011.
- [44] C. Dunne, L. O’Mahony, L. Murphy et al., “*In vitro* selection criteria for probiotic bacteria of human origin: correlation with *in vivo* findings,” *The American Journal of Clinical Nutrition*, vol. 73, no. 2, supplement, pp. 386S–392S, 2001.
- [45] R. Rubio, A. Jofré, B. Martín, T. Aymerich, and M. Garriga, “Characterization of lactic acid bacteria isolated from infant faeces as potential probiotic starter cultures for fermented sausages,” *Food Microbiology*, vol. 38, pp. 303–311, 2014.
- [46] A. A. Argyri, G. Zoumpopoulou, K.-A. G. Karatzas et al., “Selection of potential probiotic lactic acid bacteria from fermented olives by *in vitro* tests,” *Food Microbiology*, vol. 33, no. 2, pp. 282–291, 2013.
- [47] S. Lebeer, J. Vanderleyden, and S. C. J. de Keersmaecker, “Genes and molecules of lactobacilli supporting probiotic action,” *Microbiology and Molecular Biology Reviews*, vol. 72, no. 4, pp. 728–764, 2008.
- [48] L. de Vuyst and F. Leroy, “Bacteriocins from lactic acid bacteria: production, purification, and food applications,” *Journal of Molecular Microbiology and Biotechnology*, vol. 13, no. 4, pp. 194–199, 2007.
- [49] M. P. Zacharof and R. W. Lovitt, “Bacteriocins produced by lactic acid bacteria: a review article,” *APCBEE Procedia*, vol. 2, pp. 50–56, 2012.
- [50] C. A. Jacobi, S. Grundler, C. J. Hsieh et al., “Quorum sensing in the probiotic bacterium *Escherichia coli* Nissle 1917 (Mutaflor)—evidence that furanosyl borate diester (AI-2) is influencing the cytokine expression in the DSS colitis mouse model,” *Gut Pathogens*, vol. 4, no. 1, article 8, 2012.
- [51] T. T. Hove, B. van den Blink, I. Pronk, P. Drillenburgh, M. P. Peppelenbosch, and S. J. H. van Deventer, “Dichotomous role of inhibition of p38 MAPK with SB 203580 in experimental colitis,” *Gut*, vol. 50, no. 4, pp. 507–512, 2002.
- [52] L. C.-H. Yu, J.-T. Wang, S.-C. Wei, and Y. H. Ni, “Host-microbial interactions and regulation of intestinal epithelial barrier function: from physiology to pathology,” *World Journal of Gastroenterology*, vol. 3, no. 1, pp. 27–43, 2012.